BioNTech is focused on translating decades of immunology expertise into the next era of cancer care. Our goal is to combine more than 25 years of cancer immunology and genomics research with advanced technology platforms to deliver novel therapies that may transform how cancer is treated for every person.

From developing the first approved mRNA-based vaccine to building a diversified pipeline of novel oncology candidates in complementary therapeutic modalities, BioNTech’s journey has always centered around a singular belief: the immune system is a fundamental driver of therapeutic success in many diseases, including cancer.

Building on this foundation, we aim to usher in new standards of care in cancer — powered by precision, enabled by immune intelligence, and tailored to reach patients.

“At BioNTech, our long-standing mission is to harness the full power of the immune system to address some of the world’s most serious diseases,” says Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We are advancing our diversified oncology pipeline of investigational therapies into late-stage development and registrational trials either alone or as combination therapies.”

BioNTech’s multi-modality oncology pipeline consists of three complementary approaches: mRNA cancer immunotherapies, next generation immunomodulators and targeted therapies.

We believe that synergistic combinations can significantly contribute to addressing the complexity of cancer. Working together, our investigational therapies are designed to attack cancer from multiple angles: targeting multiple drivers of disease, empowering the immune system, and potentially preventing recurrence.

BioNTech is advancing two priority pan-tumor research programs: 1.) a next-generation immunomodulator being evaluated in combination with chemotherapy or antibody-drug conjugates (ADCs) to enhance efficacy; and 2.) mRNA cancer immunotherapy approaches, which include both fully individualized therapies tailored to a patient’s unique tumor mutations or tumor type-specific therapies targeting shared neoantigens. These programs aim to address the full continuum of cancer – from resected tumors in the adjuvant setting to advanced and metastatic disease – across a range of solid tumors.

“This year, our presence at ASCO reflects the growing momentum of our oncology approach. With more than 20 active Phase 2 and Phase 3 clinical trials, and a pipeline shaped by deep immunology expertise, we are aiming to advance science with intention,” says Prof. Özlem Türeci, M.D., Chief Medical Officer and Co-Founder of BioNTech. “We believe in scientific rigor, innovation and passion as the driving forces behind our work – and with every step forward, we move closer to our goal of delivering innovative next-generation cancer treatments.”

With the goal of approvals in multiple indications over the next five years, BioNTech remains focused on delivering immune-driven therapies that precisely target the right pathways for the right patients. With a pipeline rooted in scientific excellence and an unwavering commitment to patients, we’re building a future where we believe the full potential of the immune system can be realized for every person with cancer.

Learn more about our priority programs and clinical pipeline below.